Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
QuintilesIMS
Dow
Cerilliant
US Department of Justice
McKinsey
Cipla
Covington

Generated: August 14, 2018

DrugPatentWatch Database Preview

ZURAMPIC Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Zurampic patents expire, and when can generic versions of Zurampic launch?

Zurampic is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are eight patents protecting this drug.

This drug has one hundred and seventy-five patent family members in thirty-eight countries.

The generic ingredient in ZURAMPIC is lesinurad. Two suppliers are listed for this compound. Additional details are available on the lesinurad profile page.

Summary for ZURAMPIC
International Patents:175
US Patents:8
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 48
Patent Applications: 52
Drug Prices: Drug price information for ZURAMPIC
DailyMed Link:ZURAMPIC at DailyMed
Drug patent expirations by year for ZURAMPIC
Generic Entry Opportunity Date for ZURAMPIC
Generic Entry Date for ZURAMPIC*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for ZURAMPIC
(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid
{[5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-1,2,4-TRIAZOL-3-YL]SULFANYL}ACETIC ACID
{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
09ERP08I3W
2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid
2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid
2-(5-Bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid
2-[[5-Bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-acetic acid
2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid
2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]thio]acetic acid
2-{[5-broMo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
3777AH
878672-00-5
Acetic acid, 2-((5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl)thio)-
Acetic acid,[[5-bromo-4-(4-cyclopropyl-1-naphthalenyl)-4H-1,2,4-triazol-3-yl]thio]-
ACN-050764
AK323774
AKOS027327368
C17H14BrN3O2S
CHEBI:90929
CHEMBL2105720
CS-1389
D09921
D0C3SW
DB11560
EX-A1289
FGQFOYHRJSUHMR-UHFFFAOYSA-N
GTPL7673
HE067018
HY-15258
KB-78121
KS-00000LAE
LESINURAD
Lesinurad (RDEA-594)
Lesinurad (RDEA594 pound(c)
Lesinurad (RDEA594)
Lesinurad (USAN)
Lesinurad [USAN:INN]
Lesinurad, >=98% (HPLC)
MFCD22572730
MolPort-039-138-666
RDEA 594
RDEA-594
RDEA594
s4640
SC-94287
SCHEMBL842962
UNII-09ERP08I3W
W-5949
ZINC84757007
Zurampic (TN)

US Patents and Regulatory Information for ZURAMPIC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for ZURAMPIC

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,481,581 S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase ➤ Sign Up
7,435,752 N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors ➤ Sign Up
8,552,043 N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors ➤ Sign Up
8,242,154 Compounds, compositions and methods of using same for modulating uric acid levels ➤ Sign Up
7,947,721 S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for ZURAMPIC

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016024 Lithuania ➤ Sign Up PRODUCT NAME: LESINURADAS; REGISTRATION NO/DATE: EU/1/15/1080 20160218
2016000060 Germany ➤ Sign Up PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 20160218
2016 00034 Denmark ➤ Sign Up PRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222
/2016 Austria ➤ Sign Up PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 (MITTEILUNG) 20160222
16/033 Ireland ➤ Sign Up PRODUCT NAME: (I)PRODUCT (I.E. ACTIVE INGREDIENT OR COMBINATION OF ACTIVE INGREDIENTS) FOR WHICH A CERTIFICATE IS REQUESTED:-LESINURAD, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/15/1080 20160218
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Dow
Baxter
Julphar
Cerilliant
Covington
US Army
Fuji
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.